Skip to main content
Premium Trial:

Request an Annual Quote

Luminex to Collaborate with Dynacare on Clinical LabMap Tests

NEW YORK, Feb 22 - Luminex has collaborated with Dynacare, a company that runs clinical laboratories, to develop genetic tests using its LabMap technology, the companies announced Thursday.

LabMap uses microspheres to assay nucleic acids, antigen-antibody binding, enzymes, and other receptor-ligand interactions. Small lasers, digital processors, and software allow the system to perform up to 100 assays per drop of fluid. 

Under the agreement, Luminex has granted Dynacare the non-exclusive rights to develop clinical assays based on LabMap, and to purchase LabMap consumables and instruments from Luminex for its testing services. 

Dynagene, Dynacare's testing arm, will develop high-throughput diagnostic tests for cystic fibrosis and other genetic conditions such as Tay Sachs, Canavan, and Gaucher diseases. Dynagene hopes it can reduce its screening time to between one and two days, from one to two weeks for other laboratories. The parties did not disclose the financial terms of the agreement.

"We are delighted that Dynacare, a national leader in the clinical laboratory industry, has become our partner in adopting the LabMap system," said Luminex CEO Mark Chandler. "Many clinical laboratories are exploring new ways to internalize tests on the LabMap system and this agreement with Dynacare is a powerful example of how our system can be an integral solution in the clinical laboratory."

Luminex has stated that partnerships are key to the company's core marketing strategy for LabMap.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.